Comparison

Lomibuvir European Partner

Manufacturer MedChem Express
Category
Type Inhibitors
Specific against other
Amount 100mg
Item no. HY-75800-100mg
CASRN 1026785-55-6
Available
Product Description
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis.
StorageTemperature
Powder -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month
Applications
COVID-19-anti-virus
Formula
C25H35NO4S
References
[1].Yi G, Deval J, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012; 56(2):830-837. | [2].Li P, Dorsch W, et al. Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates. ACS Med Chem Lett. 2017; 8(2):251-255. Published 2017 Jan 31. | [3].M. Rodriguez-Torres et al. SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS Journal of Hepatology Volume 52, Supplement 1 , Page S14, April 2010
MolecularWeight
445.61
Research Area
Infection
Solubility
DMSO : 100 mg/mL (224.41 mM; Need ultrasonic)
Target
DNA/RNA Synthesis; HCV
Pathway
Cell Cycle/DNA Damage; Anti-infection

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

Amount: 100mg
Available: In stock
available

Delivery expected until 4/13/2023 

Compare

Add to wishlist

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close